D espite all our success in cardiology, we are still, in some ways, working at an obtuse level. We try and find individual markers for disease pathology (1), risk (2) , or for triaging patients for certain therapies (3) , and when that is not possible, we create small multivariable statistical models for prediction (4) . That strategy has worked to some extent, especially with imaging-related markers (3) , but it has also raised questions about generalizability and comparative effectiveness (4, 5) . In addition, this is a slow trial and error process (needing to find a precise variable or two), and the time line for success is uncertain (needing to test under multiple conditions and together with multiple variables).
We also understand success of therapies at a population level, hope that therapy applies to the individual patient, and often end up practicing imprecise medicine by extrapolating therapies to the wider population. This is well beyond the trial enrollment criteria or base therapies on triage variables that are themselves imprecise (e.g., triaging for implantable cardioverter-defibrillators in dilated cardiomyopathy based on ejection fraction [EF] alone).
What can hasten the process of discovery and help However, what if a single data point is not enough?
The stratification of chronic, complex disease using these simple, expert-derived algorithmic approaches is often not wholly adequate. To continue with the example of diabetes, it was recently demonstrated that type 2 diabetes is not simply a monolithic disease characterized by resistance to insulin, but instead appears to be at least 3 distinct diseases that share a number of clinical and molecular features (6) .
Subtypes clarified through advanced data analytics have prognostic import (7) . Thus, the real premise of precision cardiovascular medicine is that we can couple advanced algorithms from the fields of computer science, machine learning, and statistics with ever-accumulating, variable-rich data sets of human disease to stratify complex disease entities into new subtypes, each of which may require differential management. relationships relevant to the contents of this paper to disclose.
PRECISION MEDICINE COMES TO AORTIC STENOSIS
There has been an explosion of machine-learning approaches in cardiology (8) 
IS AS A GOOD CANDIDATE FOR SUCH PRECISION DIAGNOSTIC APPROACHES?
We have previously enumerated several criteria that indicate a disease will likely be amenable to a precision approach (19, 20) . First, diseases are primarily Chandrashekhar and Johnson
Editorial Comment 
FUTURE STEPS
The investigators presented an innovative precision medicine approach to AS. 
